LOS ANGELES, Sept. 15 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceutical Corp. (Nasdaq: RPTP). Ross Silver, Principal Analyst at Vista Partners stated, "Raptor is potentially a year away from generating revenues. Raptor currently has a balanced pipeline of clinical and preclinical programs. The Company is currently involved in four Phase 2 clinical programs and one Phase 3 trial with some indications in multi-billion dollar markets." To download a FREE copy of the Raptor Pharmaceutical Corp. research report, please visit www.vistap.com/research and complete the research form to gain access to the report.
About Vista Partners:
With offices in California and Oregon, Vista Partners LLC is one of the fastest growing independently owned research and consulting firms in the United States. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking.Contact:Phone: 877.215.4813Email: email@example.com
|SOURCE Vista Partners|
Copyright©2010 PR Newswire.
All rights reserved